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Intervention
Women were allocated to 1 daily tablet of conjugated equine oestrogen, 0.625 mg, and medroxyprogesterone acetate, 2.5 mg (n=8506), or placebo (n=8102).
Main outcome measures
Incidence of breast cancer (total, invasive, and in situ) and abnormal mammogram results.
Main results
Analysis was by intention to treat. Women who received HT had a greater incidence of total and invasive breast cancer than did women who received placebo; in situ breast cancer cases were not increased (table) . The increase in invasive breast cancer with HT was seen across almost all risk categories. Invasive breast tumours were larger in the HT group (mean 1.7 cm v 1.5 cm, p=0.04) and were diagnosed at a more advanced stage (regional or metastatic, compared with local, 25% v 16%, p=0.04) than in the placebo group. Women who received HT also had a higher proportion of abnormal mammogram results. The difference was seen at 1 year (9.4% v 5.4%, p < 0.001) and continued throughout the study (total study period 31.5% v 21.2%, p < 0.001).
Conclusion
In postmenopausal women, oestrogen plus progestogen hormone therapy increased cases of total and invasive breast cancer and abnormal mammogram results. Of note, the oestrogen only arm of the WHI is still ongoing. Women and clinicians are receiving the message that HT increases breast cancer. Placing this in perspective for the menopausal woman 2 is important because there will continue to be women who want to use HT. In women with a uterus requiring progestogen opposition, it is likely that less use of synthetic progestogens and more use of localised vaginal uterine preparations will occur, particularly if it is proven that oestrogen alone is safer from the breast cancer perspective.
*See glossary.

Oestrogen plus progestogen hormone therapy (HT) v placebo for incidence of breast cancer in postmenopausal women at mean 5.6 years †
Because HT users had a substantially greater risk of abnormal mammography results than placebo users (9.4% v 5.4%, p < 0.001), should women on HT stop using it for 2 weeks before an annual mammogram? It has been suggested that short term cessation of HT improves mammographic specificity.
3 Although screening mammography is the current gold standard, a way to detect breast cancer before finding an abnormality on mammography is needed. Ductal lavage, recently approved by the US Food and Drug Administration, can be used as a risk assessment tool for women at high risk of breast cancer who have negative results on mammography. This may help menopausal women to make well informed decisions regarding HT, the use of tamoxifen for breast cancer chemoprevention, and other decision options related to the breast. 
